(AYTU) Aytu BioScience - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0547548745
AYTU: ADHD Meds, Antihistamines, Vitamins, Fluoride Supplements
Aytu BioPharma, Inc., a pharmaceutical company, specializes in commercializing novel therapeutic drugs in the United States and internationally. The company focuses on addressing unmet medical needs, particularly in pediatric and specialty markets. Its product portfolio includes prescription medications for attention deficit hyperactivity disorder (ADHD) and allergic conditions, as well as fluoride-based supplements for children.
The companys ADHD treatment offerings include Adzenys XR-ODT, an orally disintegrating tablet (ODT) designed for patients aged six and above, and Cotempla XR-ODT, another ODT formulation approved for patients aged six to seventeen. These products provide convenient, once-daily dosing options for ADHD management. Additionally, Aytu BioPharma offers Karbinal ER, an extended-release carbinoxamine suspension for treating allergic conditions in children over two years old. The company also markets Poly-Vi-Flor and Tri-Vi-Flor, fluoride-based multi-vitamin products available in liquid and chewable tablet forms, designed to address fluoride deficiency in infants and children.
Aytu BioPharma, Inc. (NASDAQ: AYTU) has a market capitalization of $7.90M USD, with a forward P/E ratio of 0.92, indicating potential future earnings growth. The stock currently trades at $1.26, below its 20-day and 50-day moving averages of $1.32 and $1.53, respectively, but above its 200-day moving average of $2.16. The average true range (ATR) of 0.09 suggests low volatility in recent trading. The companys price-to-book (P/B) ratio of 0.25 and price-to-sales (P/S) ratio of 0.10 highlight its undervalued status relative to book value and revenue. However, the negative return on equity (RoE) of -17.05% reflects operational challenges.
Over the next three months, Aytu BioPharmas stock is expected to remain under pressure due to its current downtrend, as indicated by its position below the 20-day and 50-day SMAs. However, the low ATR suggests limited downside potential. The companys fundamental outlook is mixed, with undervalued metrics such as P/B and P/S offset by a negative RoE. If Aytu BioPharma can demonstrate progress in improving profitability or achieving positive earnings, the stock may stabilize or experience upward momentum. Otherwise, it is likely to remain range-bound or decline further.
Additional Sources for AYTU Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AYTU Stock Overview
Market Cap in USD | 8m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2017-02-01 |
AYTU Stock Ratings
Growth 5y | -97.4% |
Fundamental | 18.1% |
Dividend | 0.0% |
Rel. Strength Industry | -58.4 |
Analysts | 4/5 |
Fair Price Momentum | 0.41 USD |
Fair Price DCF | 1.70 USD |
AYTU Dividends
No Dividends PaidAYTU Growth Ratios
Growth Correlation 3m | -60% |
Growth Correlation 12m | -94.2% |
Growth Correlation 5y | -93.6% |
CAGR 5y | -67.11% |
CAGR/Max DD 5y | -0.67 |
Sharpe Ratio 12m | -0.08 |
Alpha | -66.77 |
Beta | 0.70 |
Volatility | 68.53% |
Current Volume | 21.6k |
Average Volume 20d | 40.6k |
As of March 15, 2025, the stock is trading at USD 1.20 with a total of 21,633 shares traded.
Over the past week, the price has changed by -3.61%, over one month by -13.00%, over three months by -13.94% and over the past year by -58.02%.
Neither. Based on ValueRay Fundamental Analyses, Aytu BioScience is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 18.10 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AYTU as of March 2025 is 0.41. This means that AYTU is currently overvalued and has a potential downside of -65.83%.
Aytu BioScience has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy AYTU.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AYTU Aytu BioScience will be worth about 0.5 in March 2026. The stock is currently trading at 1.20. This means that the stock has a potential downside of -61.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8 | 566.7% |
Analysts Target Price | 8 | 566.7% |
ValueRay Target Price | 0.5 | -61.7% |